Literature DB >> 23224499

Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis?

Mislav Radić1, Dušanka Martinović Kaliterna, Damir Bonacin, Jadranka Morović Vergles, Josipa Radić, Damir Fabijanić, Vedran Kovačić.   

Abstract

Helicobacter pylori (H. pylori) is suspected to be one of the factors triggering systemic sclerosis (SSc). Data on the possible role of H. pylori are lacking. The aim of this study was to assess the effect of H. pylori infection in SSc patients. Forty-two SSc patients without dyspeptic symptoms were recruited--26 were H. pylori-positive and 16 were H. pylori-negative on the basis of invasive test. We evaluated the disease severity using clinical and laboratory parameters according to the Medsger Severity Scale. The level of SSc activity was evaluated according to Valentini activity score. The prevalence of H. pylori infection in population of SSc patients is 62%. Severity of skin, gastrointestinal, and joint/tendon involvement was different between H. pylori-positive and -negative SSc patients (p < 0.001 for skin involvement, p = 0.002 and p = 0.03 for gastrointestinal and joint/tendon involvement, respectively) as well as erythrocyte sedimentation rate (p = 0.002). Severity score according to Medsger was higher in the H. pylori-positive than in the H. pylori-negative SSc patients (p < 0.001). Our data suggest that H. pylori infection correlates with severity of skin, gastrointestinal, and joint/tendon involvement in SSc patients. H. pylori-positive SSc patients showed higher severity score compared to H. pylori-negative. Therefore, H. pylori infection may play a role in the pathogenesis of SSc and also can provide some prognostic information.

Entities:  

Mesh:

Year:  2012        PMID: 23224499     DOI: 10.1007/s00296-012-2585-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis.

Authors:  S Danese; A Zoli; F Cremonini; A Gasbarrini
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

Review 2.  The role of infectious agents in the pathogenesis of systemic sclerosis.

Authors:  Damir Hamamdzic; Laura M Kasman; E Carwile LeRoy
Journal:  Curr Opin Rheumatol       Date:  2002-11       Impact factor: 5.006

Review 3.  Assessment of disease severity and prognosis.

Authors:  T A Medsger; S Bombardieri; L Czirjak; R Scorza; A Della Rossa; W Bencivelli
Journal:  Clin Exp Rheumatol       Date:  2003       Impact factor: 4.473

Review 4.  Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis.

Authors:  M Radić; D Martinović Kaliterna; J Radić
Journal:  Neth J Med       Date:  2010-11       Impact factor: 1.422

5.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

6.  [Distribution of Helicobacter pylori infection in the adult population of Croatia].

Authors:  V Babus; V Presecki; M Katicić; M Balija; I Zorić; L Kronja; A Sabo; J Vrlicak; S Cuković-Cavka
Journal:  Lijec Vjesn       Date:  1997 May-Jun

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 8.  Role of infectious agents in systemic rheumatic diseases.

Authors:  H Amital; M Govoni; R Maya; P L Meroni; B Ori; Y Shoenfeld; A Tincani; F Trotta; P Sarzi-Puttini; F Atzeni
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

Review 9.  The prevalence of Helicobacter pylori infection in different countries.

Authors:  R E Pounder; D Ng
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

10.  Molecular mimicry between Helicobacter pylori antigens and H+, K+ --adenosine triphosphatase in human gastric autoimmunity.

Authors:  Amedeo Amedei; Mathijs P Bergman; Ben J Appelmelk; Annalisa Azzurri; Marisa Benagiano; Carlo Tamburini; Ruurd van der Zee; John L Telford; Christina M J E Vandenbroucke-Grauls; Mario M D'Elios; Gianfranco Del Prete
Journal:  J Exp Med       Date:  2003-10-20       Impact factor: 14.307

View more
  10 in total

Review 1.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

Review 2.  Role of Helicobacter pylori infection in autoimmune systemic rheumatic diseases.

Authors:  Mislav Radić
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

3.  Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis.

Authors:  Georgios Efthymiou; Christos Liaskos; Theodora Simopoulou; Emmanouela Marou; Eleni Patrikiou; Thomas Scheper; Wolfgang Meyer; Dimitrios Daoussis; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 4.  Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment.

Authors:  Traci L Testerman; James Morris
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Helicobacter pylori and autoimmune disease: cause or bystander.

Authors:  Daniel S Smyk; Andreas L Koutsoumpas; Maria G Mytilinaiou; Eirini I Rigopoulou; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 6.  Factors associated with development of gastrointestinal problems in patients with scleroderma: a systematic review.

Authors:  Brian Younho Hong; Raymond Giang; Lawrence Mbuagbaw; Maggie Larche; Lehana Thabane
Journal:  Syst Rev       Date:  2015-12-30

7.  Helicobacter pylori infection and severity of coronary atherosclerosis in patients with chronic coronary artery disease.

Authors:  Anita Jukic; Dorotea Bozic; Dusko Kardum; Tina Becic; Bruno Luksic; Mislav Vrsalovic; Marko Ljubkovic; Damir Fabijanic
Journal:  Ther Clin Risk Manag       Date:  2017-07-27       Impact factor: 2.423

Review 8.  Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.

Authors:  Marta Cossu; Lorenzo Beretta; Petra Mosterman; Maria J H de Hair; Timothy R D J Radstake
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

9.  Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Socorro Méndez-Martínez; Tania Mogollán-Delfín; Pamela Munguía-Realpozo; Efrén Herrera-Robles; Ivet Etchegaray-Morales; José Luis Gálvez-Romero; Álvaro Montiel-Jarquín; Aurelio López-Colombo
Journal:  Clin Rheumatol       Date:  2019-11-12       Impact factor: 2.980

10.  Type B insulin resistance syndrome with Scleroderma successfully treated with multiple immune suppressants after eradication of Helicobacter pylori infection: a case report.

Authors:  Guo-Qing Yang; Yi-Jun Li; Jing-Tao Dou; Bao-An Wang; Ju-Ming Lu; Yi-Ming Mu
Journal:  BMC Endocr Disord       Date:  2016-05-03       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.